NCT06908733View on ClinicalTrials.gov

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 30, 2029

Conditions

Non-Small Cell Lung Cancer (Stage III)

Interventions

DRUG

3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.

Patients deemed eligible to surgery will receive standard lung cancer resection (excluding total pneumonectomy)

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER